|Year : 2022 | Volume
| Issue : 4 | Page : 904-905
Letrozole-induced bilateral acute intermediate uveitis with cystoid macular edema
Rajlaxmi Virkar1, Madhuri Meshram1, Amit S Nene1, Onkar H Pirdankar2, Pushpanjali Ramteke1, Smitesh Shah1
1 Department of Ophthalmology, Isha Netralaya, Kalyan, Maharashtra, India
2 Department of Optometry, Isha Netralaya, Kalyan, Maharashtra, India
|Date of Submission||22-Mar-2022|
|Date of Acceptance||06-Jun-2022|
|Date of Web Publication||11-Oct-2022|
Mr. Onkar H Pirdankar
Isha Netralaya, Radhakrishna Sankul, Opp Holy Cross Hospital, Karnik Road, Kalyan, Maharashtra – 421 301
Source of Support: None, Conflict of Interest: None
The purpose is to report a rare case of letrozole-induced bilateral acute intermediate uveitis (IU) with cystoid macular edema (CME). A 29 years old female undergoing infertility treatment came with complaints of progressive diminution of vision in both eyes. Clinical evaluation and optical coherence tomography (OCT) revealed IU with CME in both eyes. Intravitreal steroid injections and discontinuation of oral letrozole led to the resolution of IU with CME. Thus, all patients who are treated with letrozole should undergo periodic ophthalmic screening for timely diagnosis and treatment.
Keywords: Cystoid macular edema, infertility, letrozole, pars planitis
|How to cite this article:|
Virkar R, Meshram M, Nene AS, Pirdankar OH, Ramteke P, Shah S. Letrozole-induced bilateral acute intermediate uveitis with cystoid macular edema. Indian J Ophthalmol Case Rep 2022;2:904-5
|How to cite this URL:|
Virkar R, Meshram M, Nene AS, Pirdankar OH, Ramteke P, Shah S. Letrozole-induced bilateral acute intermediate uveitis with cystoid macular edema. Indian J Ophthalmol Case Rep [serial online] 2022 [cited 2022 Nov 27];2:904-5. Available from: https://www.ijoreports.in/text.asp?2022/2/4/904/358187
Letrozole is an oral non-steroidal third-generation aromatase inhibitor (AI). It is used as an adjunct for intrauterine insemination (IUI), in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and endometrium preparation for frozen-thawed embryos transfer (FET). Infertility is a serious health issue worldwide with a prevalence of 8.9% among reproductive age group women.
Ocular side effects due to other AIs such as anastrozole have been described previously and include dry eyes, Meibomian gland More Details dysfunction, keratopathy, uveitis, macular edema, macular hole, optic neuritis, etc. Here we describe a rare clinical presentation of letrozole-induced bilateral acute intermediate uveitis (IU) with macular edema since there is limited literature about it.
| Case Report|| |
A 29-year-old female visited the outpatient department with gradual, painless, progressive diminution of vision in both eyes since 1 week. There was a history of multiple failed IUIs and her anti-Mullerian hormone (AMH) level was found to be 1.97, which indicated low fertility. There were four cycles of ovarian stimulation, which comprised of letrozole. After the fourth cycle, the patient noticed redness in both eyes. On examination, her best-corrected distance and near visual acuity in both eyes were 6/18 and N8, respectively, with no further improvement with the pinhole. Anterior segment evaluation showed minimal conjunctival congestion with cells 2 + in the anterior chamber. Intraocular pressure was normal in both eyes. On fundus examination, vitritis with dull foveal reflex was seen in both eyes. Optical coherence tomography (OCT) revealed cystoid macular edema (CME) in both eyes [Figure 1]. Complete blood count and chest X-ray were normal while Mantoux test, anti-nuclear antibody test, venereal disease research laboratory (VDRL), and Treponema pallidum magglutination (TPHA) were negative. The patient did not consent to systemic steroids in view of ongoing infertility treatment and requested for a local alternative. In addition, the patient had stopped oral letrozole after consulting a gynecologist. Thus, in view of bilateral significant CME, intravitreal dexamethasone implant (Ozurdex) in both eyes in a gap of 2 days was given along with topical steroids (prednisolone acetate 1%) and mydriatic (atropine sulfate 1%) eye drops. At 2 weeks of follow-up, resolved vitritis and CME were noted with subsequent improvement in vision in both eyes to 6/6, N6 [Figure 2].
|Figure 1: Fundus photo and OCT of both eyes showing cystoid macular edema|
Click here to view
| Discussion|| |
Here we describe a case of letrozole-induced bilateral IU with CME, which was resolved with intravitreal dexamethasone implant, and discontinuation of letrozole.
Letrozole blocks estrogen synthesis by inhibiting the final step of the estrogen biosynthetic pathway and thus it is used in the management of infertility in females. Dose administration has generally been limited to 5 days at 2.5 to 7.5 mg daily which can be increased to 12.5 mg daily. AIs offer more physiologic hormonal stimulation of the endometrium, a lower multiple-pregnancy rate through single-follicle recruitment, a better side effect profile with fewer vasomotor and mood symptoms, and more rapid clearance, thus reducing the chances of periconceptional exposure. The systemic adverse effects of AI from their long-term use are well documented and include joint disorders, skeletal complications, cardiotoxicity, headache, hot flashes, abdominal bloating, and abdominal pain including cramps.,
The previous report has shown letrozole-induced unilateral macular edema which improved after intravitreal injection of ranibizumab. To the best of our knowledge, this is the first report which describes the letrozole-induced bilateral presentation of acute IU with CME. Letrozole may deprive the retina and the choroid of the beneficial, protective effects mediated by estrogens. The restriction of estrogen-mediated neuroprotection in the retina causes the breakdown of the blood-retinal barrier.
Thus, all patients who are treated with letrozole should undergo periodic ophthalmic screening for timely diagnosis and treatment.
| Conclusion|| |
We have presented a rare clinical presentation of letrozole-induced bilateral acute IU with cystoid macular edema. Clinicians should be aware of this possible side-effect.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Serban D, Costea DO, Zgura A, Tudosie MS, Dascalu AM, Gangura GA, et al.
Ocular side effects of aromatase inhibitor endocrine therapy in breast cancer – A review. In Vivo
Yang AM, Cui N, Sun YF, Hao GM. Letrozole for female infertility. Front Endocrinol (Lausanne) 2021;12:1–8.
Katole A, Saoji AV. Prevalence of primary infertility and its associated risk factors in urban population of Central India: A community-based cross-sectional study. Indian J Community Med 2019;44:337–41.
] [Full text]
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al.
Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014;371:119-29.
Almafreji I, Smith C, Peck F. Review of the literature on ocular complications associated with aromatase inhibitor use. Cureus 2021;13:8–11.
Moschos MM, Chatziralli IP, Zagouri F, Zografos GC. Macular oedema due to letrozole: A first case report. Clin Exp Optom 2012;95:646–50.
[Figure 1], [Figure 2]